Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation (PSD502-PE-002)

This study has been completed.
Sponsor:
Collaborator:
Shionogi Inc.
Information provided by:
Plethora Solutions Ltd
ClinicalTrials.gov Identifier:
NCT00556478
First received: November 9, 2007
Last updated: July 14, 2010
Last verified: July 2010
  Purpose

The purpose of this study is to evaluate the effectiveness, safety and tolerability of the investigational drug, PSD502 in subjects with premature ejaculation (PE) The study drug, PSD02, is a metered dose (measured dose), topical (applied to the skin surface) anesthetic (numbing) spray containing a mixture of lidocaine and prilocaine. The study drug will be applied in a spray to the penis prior to intercourse in order to decrease sensitivity in an attempt to delay ejaculation.


Condition Intervention Phase
Premature Ejaculation
Drug: PSD502, contains a mixture of lidocaine and prilocaine
Drug: PSD502 Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase IIb, Multi-center, Randomized, Double-blind, Placebo-controlled Study, With Open-label Follow on, to Evaluate the Efficacy, Safety and Tolerability of PSD502 in Subjects With Premature Ejaculation (PE)

Resource links provided by NLM:


Further study details as provided by Plethora Solutions Ltd:

Primary Outcome Measures:
  • To evaluate efficacy of treatment with PSD502 compared with placebo in subjects with PE as measured by: • changes in mean IELT from baseline to during 3 month double-blind treatment • changes in all 3 IPE domains from baseline to month 3 [ Time Frame: 3 Months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of subjects with short mean IELT during double-blind treatment; Change in mean IELT from Baseline; Subject & Partner PEP scores; Evaluation of safety and tolerability measured by Adverse Event data [ Time Frame: 3 Months ] [ Designated as safety issue: No ]

Enrollment: 256
Study Start Date: October 2007
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Double-Blind Active
Double-blind Phase: Subjects will be randomised in a 2:1 ratio of PSD502 or placebo respectively if the patient meets all the entry criteria.
Drug: PSD502, contains a mixture of lidocaine and prilocaine

PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.

Approximately 5 minutes before intercourse the study spray (PSD502 or Placebo) can be applied and any excess should be wiped off with a damp cloth or tissue.

During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing

During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period.

Placebo Comparator: Double-Blind Placebo
Double-blind Phase: Subjects will be randomised in a 2:1 ratio of PSD502 or placebo respectively if the patient meets all the entry criteria.
Drug: PSD502 Placebo

The placebo is a metered dose aerosol spray that is identical in appearance to the PSD502 spray and contains the same propellant (norflurane) but has no lidocaine or prilocaine.

Approximately 5 minutes before intercourse the study spray (PSD502 or Placebo) can be applied and any excess should be wiped off with a damp cloth or tissue.

During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.

During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period.

Active Comparator: Open Label Phase
Subjects will all receive PSD502 if they wish to continue in the trial.
Drug: PSD502, contains a mixture of lidocaine and prilocaine

PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.

Approximately 5 minutes before intercourse the study spray (PSD502 or Placebo) can be applied and any excess should be wiped off with a damp cloth or tissue.

During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing

During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period.


Detailed Description:

Most studies evaluating treatments PE include intravaginal ejaculatory latency time (IELT) in the definition of PE. It has been estimated that PE affects 30-40% of the male population, but is paradoxically a condition for which they are least likely to seek help.

Men with PE exhibit abnormal autonomic reflex pathways for the ejaculatory process. These include lower vibratory threshold to ejaculation, shorter bulbocavernous latency time and higher bulbocavernous evoked potentials. Reducing the heightened sensitivity of the glans penis with topical anesthetics might therefore be a way of improving IELT, without adversely affecting the sensation of ejaculation.

Although IELT is an objective measure of ejaculatory function it does not address the impact of therapy on patients' well being and confidence in their sexual performance, which are important markers of treatment benefit. Therefore, if IELT is used as a sole efficacy measure it may not fully characterise the treatment benefit to the patient. For this reason, a patient reported outcome (PRO) known as the Index of Premature Ejaculation (IPE) will be used in this study in conjunction with IELT to evaluate efficacy. Thus the combination of the objective measure of ejaculatory latency with the PRO of IPE should be able to provide efficacy data which are representative of clinical benefit to the patient.

The use of lidocaine, prilocaine and EMLA® cream as topical anesthetics is well established. Many years of experience of use in large numbers of patients, as well as comprehensive non-clinical safety testing programs for various formulations of lidocaine and prilocaine exist, to support their safety and tolerability. This information, together with the clinical data from 3 studies with PSD502 (ANAE-059-00, PSD502-PE-001, and PSD502-PE-003), suggest that PSD502 may have beneficial effects in reducing penile sensation and prolonging IELT, and its use is unlikely to be associated with significant clinical safety or tolerability concerns.

The aim of this study is to provide additional placebo-controlled efficacy data to establish the clinical utility of PSD502 in the treatment of PE. In addition, long term open-label efficacy and safety data will be collected, to further support the registration package for PSD502 in the indication of treatment of PE.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willing and able to provide written informed consent.
  • Male and aged 18 years and over.
  • Diagnosed with PE according to DMS-IV criteria and ISSM definition
  • Diagnosed with lifelong PE
  • Acceptable response to Baseline PEP
  • Subject must be in a stable heterosexual and monogamous relationship and the partner must provide consent
  • Acceptable sexual encounters in the Baseline period.

Exclusion Criteria:

  • Subject, or his sexual partner, has received an investigational (non-registered) drug within 30 days of Screening.
  • Subject has erectile dysfunction
  • The subject, or his sexual partner, has a physical or psychological condition that would prevent them from undertaking the study procedures, including, but not limited to, the following:

    • Urological disease
    • Ongoing significant psychiatric disorder not controlled by medication.
  • Subject has safety testing abnormalities at the Screening Visit
  • Subjects taking excluded medications or receiving any treatment for PE
  • Subject, or his sexual partner, has a current history of alcohol or drug abuse,
  • The subject, or his sexual partner, is unlikely to understand or be able to comply with study procedures, for whatever reasons.
  • Subject, or his sexual partner, has known drug sensitivity to amide-type local anesthetics.
  • Subjects with pregnant partners
  • Subject with sexual partners of child-bearing potential and not using appropriate contraception
  • Subject, or his sexual partner, has a history of Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency or use of medications that would increase susceptibility to methemoglobinemia (e.g. anti-malarial agents).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00556478

Locations
United States, North Carolina
Department of Urology, University of North Carolina
Chapel Hill, North Carolina, United States, 27599 - 7254
Sponsors and Collaborators
Plethora Solutions Ltd
Shionogi Inc.
Investigators
Principal Investigator: Culley Carson, MD University of North Carolina
  More Information

Publications:
Responsible Party: Dr Steven Powell, Plethora Solutions Ltd
ClinicalTrials.gov Identifier: NCT00556478     History of Changes
Other Study ID Numbers: PSD502-PE-002
Study First Received: November 9, 2007
Last Updated: July 14, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Plethora Solutions Ltd:
Premature Ejaculation
Lidocaine
Prilocaine
EMLA® cream
topical anesthetics

Additional relevant MeSH terms:
Premature Ejaculation
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Sexual and Gender Disorders
Mental Disorders
Anesthetics
Prilocaine
Lidocaine
EMLA
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Cardiovascular Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anesthetics, Combined

ClinicalTrials.gov processed this record on July 31, 2014